Study wrapper · #1340
Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.
Editor's note
The most actionable point is diagnostic rather than pharmacological: the authors want noninvasive fibrosis scoring used routinely in high-risk kidney-disease cohorts. On drugs, they read the recent trial set as evidence that incretin agents act across the whole cardiovascular-renal-hepatic-metabolic spectrum rather than on a single organ. Nomenclature is explicitly unsettled here, so the acronym itself should be regarded as provisional.
Plain-language abstract
This review argues the liver belongs inside the cardiovascular-kidney-metabolic disease framework, since having both fatty liver disease and chronic kidney disease carries a higher mortality risk than either alone, with fibrosis severity rather than fat accumulation the dominant driver. It summarises recent approvals, including semaglutide across the FLOW, SELECT and SMART kidney trials and for MASH after ESSENCE, plus tirzepatide in obesity-related heart failure with preserved ejection fraction.